AXS-17
AXS-17, also known as BAER-101 or as AZD-7325, is a GABAA receptor positive [allosteric modulator|GABAA receptor positive allosteric modulator] and nonbenzodiazepine which is under development for the treatment of anxiety disorders and absence epilepsy. It is or was also under development for autism spectrum disorder, fragile X syndrome, and other neurological disorders, but no recent development has been reported for these indications. The drug is a GABAA receptor α2 and α3 subunit-selective partial positive allosteric modulator acting via the benzodiazepine site. It might have reduced side effects compared to non-selective high-efficacy positive allosteric modulators like the benzodiazepines diazepam and lorazepam. In terms of chemical structure, AXS-17 is a cinnoline derivative. AXS-17 was originated by AstraZeneca and the University [College London]. It was licensed and under development by Avenue Therapeutics's Baergic Bio, but was later acquired by Axsome Therapeutics, which is now developing the drug. As of November 2025, AXS-17 is in phase 2 clinical trials for anxiety disorders and is in the preclinical research stage of development for absence epilepsy. AXS-17 was first described in the scientific literature by at least 2012.